ProQR Therapeutics NV
PRQR
View Detailed Chart
1.500USD
+0.040+2.74%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
161.57MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.74%
5 Days
-7.41%
1 Month
-27.88%
6 Months
-27.18%
Year to Date
-25.74%
1 Year
-37.50%
View Detailed Chart
TradingKey Stock Score of ProQR Therapeutics NV
Currency: USD Updated: 2026-02-06Key Insights
ProQR Therapeutics NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 137 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ProQR Therapeutics NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ProQR Therapeutics NV Highlights
StrengthsRisks
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 348.01% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.01M.
Overvalued
The company’s latest PE is -4.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.27M shares, decreasing 10.09% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 750.00K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
9.000
Target Price
+516.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ProQR Therapeutics NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ProQR Therapeutics NV Info
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Ticker SymbolPRQR
CompanyProQR Therapeutics NV
CEOde Boer (Daniel Anton)
Websitehttps://www.proqr.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68902.710
-1067.420 (-1.53%)
282.580
+22.390 (+8.61%)
2049.400
-2.330 (-0.11%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
